TWIST1 Promotes Colorectal Carcinoma Stemness and Oxaliplatin Resistance by Activating Microfibrillar-Associated Protein 2.Colorectal carcinoma (CRC) is a fatal disease and ranks as the third most prevalent cancer globally.  This study attempted to probe the impact of TWIST1 on CRC stemness and resistance to oxaliplatin and to uncover the underlying regulatory mechanism of TWIST1.  Quantitative real-time polymerase chain reaction was used to assess TWIST1 and microfibrillar-associated protein 2 (MFAP2) levels in CRC and normal cells. 
TWIST1
mRNA expression data from The Cancer Genome Atlas-CRC were subjected to differential analysis. 
The Cancer Genome Atlas-CRC
ChIPBase was utilized to predict likely targets downstream of the target gene. 
ChIPBase
Pearson was employed for correlation analysis. 
Pearson
Quantitative real-time polymerase chain reaction was used to assess TWIST1 and microfibrillar-associated protein 2 (MFAP2) levels in CRC and normal cells. 
Quantitative real-time polymerase chain reaction
The cell viability was assayed through cell counting kit-8 and IC
cell counting kit-8